Ventures focusing on gene therapy, adoptive T-cell therapy, protein homeostasis and the microbiome are among those selected by the editors in 2013's crop of startups.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bouchie, A., Allison, M., Webb, S. et al. Nature Biotechnology's academic spinouts of 2013. Nat Biotechnol 32, 229–238 (2014). https://doi.org/10.1038/nbt.2846
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2846
This article is cited by
-
Evolution of CAR T-cell immunotherapy in terms of patenting activity
Nature Biotechnology (2019)
-
Induced protein degradation: an emerging drug discovery paradigm
Nature Reviews Drug Discovery (2017)
-
Epic $12 billion deal and FDA's approval raise CAR-T to new heights
Nature Biotechnology (2017)
-
Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies
Cancer Gene Therapy (2015)
-
Nature Biotechnology's academic spinouts of 2014
Nature Biotechnology (2015)